BioXcel Therapeutics, Inc. BTAI 深 沪
等待开盘 03-28 09:30:00 美东时间
1.26
-0.110
-8.03%
华盛通- 最 高1.83
- 今 开1.42
- 成交量 95.59万股
- 最 低 1.25
- 昨 收 1.37
- 总市值 3.53万
- 52周最高 8.08
- 市盈率 静 --
- 换手率 3415.87%
- 52周最低 1.17
- 委 比 89.12%
- 总股本 2.80万
- 历史最高 71.50
- 量 比 1.75
- 振 幅 42.34%
- 历史最低 0.16
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
BioXcel Therapeutics Commences ~$8M Offering Of Common Stocks, Warants
BioXcel Therapeutics, Inc. (the "Company") (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a
03-11 02:37
BioXcel Therapeutics Stock Rallies Opioid Study Success
BioXcel Therapeutics' stock rises premarket after Phase 2 data show BXCL501 reduced opioid withdrawal symptoms and may rival Lucemyra.
03-05 21:53
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended continuing BioXcel's Phase 3 SERENITY At-Home trial of BXCL501 for agitation in bipolar or schizophrenia patients. The trial, with over 200 patients fully enrolled, expects Q3 2025 topline data; the company aims to expand IGALMI's label for home use, addressing an unmet need.
2025-05-27 12:01
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
BioXcel Therapeutics, Inc. has been granted continued listing on the Nasdaq Stock Market after demonstrating its compliance plan to meet listing requirements by September 2025. The company is advancing its Phase 3 SERENITY trial to support a potential sNDA submission for BXCL501, aiming to expand the IGALMI label. CEO Vimal Mehta emphasized the company's commitment to delivering value through strategic initiatives.
2025-05-27 11:00
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.
2024-09-06 19:35
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.
2024-08-30 23:42
